Vapotherm Blog

CAUTION: US Federal law restricts this device to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at https://vapotherm.com/resources/support/precision-flow-reference/. For spontaneously breathing patients. High Velocity Therapy (HVT) does not provide total ventilatory requirements of the patient. It is not a ventilator. Decisions surrounding patient care depend on the physician’s professional judgment in consideration of all available information for the individual case, including escalation of care depending on patient condition. 

Vapotherm provides high velocity nasal insufflation (HVNI) with simultaneous oxygen delivery to augment breathing of spontaneously breathing patients suffering from respiratory distress and/or hypoxemia in the hospital setting. It is not intended to provide total ventilatory requirements of the patient and not for use during field transport. 
The information provided in this section is for educational purposes only. This information is not intended to support the safety or effectiveness of Vapotherm products, or diagnose, treat, cure, or prevent any disease. It is not a substitute for consultation with your healthcare provider and should not be construed as medical advice. 

faint image of a doctor speaking with a patient behind the letters US Food and Drug Administration

FDA Grants Vapotherm’s De Novo Request for New Category for Precision Flow Hi-VNI System

The U.S. Food and Drug Administration (FDA) granted Vapotherm’s request for a new category (QAV), and expanded indications for the latest version Precision Flow, the Precision Flow Hi-VNITM system. The indication now states this system may be used to augment breathing of spontaneously breathing patients suffering from respiratory distress in the acute setting.

Image of a patient taking oral medication while on Vapotherm high velocity therapy

What is Mask-Free NIV?

For patients in respiratory distress, non-invasive positive pressure ventilation (NiPPV) has been the first-line approach for decades. It’s a respected standard of care, but not all patients can tolerate this mask-based therapy.

Close up image of a Precision Flow system’s screen

How to Select Clinically Effective Liter Flows for Hypercapnic Patients?

Vapotherm’s Hi-VNI® Technology can be used to treat respiratory distress in hospital settings. Vapotherm does not practice medicine or provide medical services. These guidelines are based on an assessment of peer-reviewed published literature, physician interviews, and physiological modeling. Providers should refer to the full indications for use, operating instructions, and prescribing information of any products referenced herein before prescribing them.

Image of a hospital room with a patient in the distance and a vitals monitor in the front

New Randomized Controlled Trial Recommends Vapotherm High Velocity Therapy as Front-Line Tool for Patients Admitted to ICU with Severe Bronchiolitis

In June 2018, Ergul and colleagues published the results of a single-center, randomized controlled trial in the European Journal of Pediatrics titled “Using a high-flow nasal cannula provides superior results to OxyMask delivery in moderate to severe bronchiolitis: a randomized controlled study.”

image of a jar of pills that says “sedative”

Study Suggests Sedation May Prevent NIV Failure, but Continuous Sedation May Increase Mortality in DNI Patients

In July 2015, Matsumoto and colleagues published the results of a retrospective, single-center study in BMC Pulmonary Medicine titled “Role of sedation for agitated patients undergoing noninvasive ventilation: clinical practice in a tertiary referral hospital.” The study examined records of 3506 consecutive patients that had been placed on noninvasive ventilation (NIV).

image of a jar of medication that says Dexmedetomidine

Dexmedetomidine During Noninvasive Ventilation: Dr. Shein from Rainbow Babies and Children’s Hospital Cleveland, OH Comments

In April 2018, Steven Shein, MD from Rainbow Babies and Children’s Hospital Cleveland, OH’s Division of Pediatric Critical Care Medicine, Department of Pediatrics, published an editorial in in Pediatric Critical Care Medicine titled “Dexmedetomidine During Noninvasive Ventilation: Different Acuity, Different Risks?.”

Image of Dr. Johnson laughing with a patient

New Study Finds 33% Mortality Rate for Older Adults After Intubation

In March 2018, Ouchi and colleagues published the results of a retrospective cohort study in the Journal of American Geriatrics Society titled “Prognosis After Emergency Department Intubation to Inform Shared Decision-Making.”

Blue graphic that says DNI with the pharmacy symbol

New Meta-Analysis Shows NIV Achieves Survival without Decrease of Life Quality for Patients on DNI Orders

In August 2018, Wilson and colleagues published the results of a systemic review and meta-analysis in Critical Care Medicine titled “Noninvasive Ventilation in Patients With Do-Not-Intubate and Comfort-Measures-Only Orders: A Systematic Review and Meta-Analysis.”

Image of Chris Price with a play button over him

BreatheTV Episode 20: NTI 2018 | No Mask. No Problem.

No mask. No problem.™

Image of a sleeping pediatric patient surrounded by a medical team

Extubation in the Pediatric Intensive Care Unit

Vapotherm’s Hi-VNI® Technology is a tool for treating respiratory distress in hospital settings. The views and ideas presented in this video are solely those of the speaker, and the content is not intended to serve as medical advice. Vapotherm does not practice medicine or provide medical services.